Seres Therapeutics (MCRB) Misses Q3 EPS by 6c

Seres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.38), $0.06 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apple’s big price hike seen as "an unprecedented push to protect margins"
• Darden Restaurants (DRI) PT Raised to $240 at UBS as Stock Remains a 'Quality Compounder'